The global erdosteine market is expected to grow from USD 143 million in 2022 to USD 341.96 million by 2032, at a CAGR of 9.11% from 2023-2030. The increasing incidence of chronic obstructive pulmonary diseases will augment the growth of the global erdosteine market.
The changing environment, with a rise in air pollution and increased cigarette or tobacco consumption, has led to a rise in respiratory diseases and conditions. Prolonged exposure to chemicals in industrial units or indoor pollution in the countryside also contributes to the rising prevalence of lung diseases/disorders. The airflow obstruction can lead to persistent coughing, wheezing, nausea or vomiting. It can also degrade the quality of life for suffering individuals. These conditions can turn fatal if not managed or treated. They can also contribute to the incidence of other severe health conditions of the heart or kidneys. Erdosteine is a mucolytic agent which is highly effective in clearing the airway. It effectively treats or clinically manages chronic obstructive pulmonary diseases and chronic bronchitis. It helps in improving the quality of life.
Get an overview of this study by requesting a free sample
In October 2020 – covid 19 pandemic left the respiratory systems infected with long-term repercussions, including dyspnea, exhaustion, and a chronic cough. This condition is referred to as "long COVID" as a whole. For COVID-19 patients to regain their quality of life, finding treatments that can lessen the condition's long-term impacts will be essential. Erdosteine is a recently discovered chemical that has the potential to enhance pulmonary function in long-COVID patients significantly. Erdosteine is given in more than 40 nations worldwide due to its well-established therapeutic benefit in patients with acute and chronic respiratory problems. Erdosteine's usage as a successful treatment for long-COVID was tested during the pandemic in numerous countries due to its effectiveness in recovering respiratory function in people suffering from illnesses like pneumonia. After encouraging findings on Erdosteine's suitability as a long-COVID treatment, Edmond Pharma undertook process development work to create a workable commercial manufacturing method for Erdosteine with the assistance of Recipharm.
The rising prevalence of chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseases are a group of conditions that affect the respiratory tracts or lungs. It leads to airway obstruction; the airway can narrow, causing breathing problems. These conditions are chronic and can get worse over time. Millions of people die annually globally, most of whom are below 70 and belong to low and middle-income countries. The problems with breathing can lead to increased coughing, wheezing, and shortness of breath, mucus production, and chest tightness, among others. These conditions, if not treated, can lead to other severe heart conditions, lung cancers, musculoskeletal disorders and other mental anguishes. The common causes are occupational exposure to undesirable chemicals, tobacco consumption, cigarette smoking, and exposure to exhaust air pollution. Given the increasing number of vehicles on the road, industrial units and other manufacturing services, the growing urban pollution has contributed to the rising incidence of chronic respiratory conditions. The changing environmental needs have led to intense smog enveloping entire cities, causing unwanted and extended exposure to undesirable particles. The growing urban population and congestion are also significantly degrading the air quality. The use of wood as fuel for cooking and other domestic purposes in rural areas has also increased exposure to burn and smoke, leading to chronic lung conditions. The lifestyle changes have led to no physical exercise, increased tobacco consumption and smoking, gave the rising stress levels of the modern world. These conditions can be life-threatening if not treated on time. Erdosteine is a mucolytic agent that aids in managing the symptoms of chronic obstructive pulmonary diseases, thereby allowing the patients to improve their quality of life and go about everyday activities without any hindrance. Therefore, the rising chronic obstructive pulmonary disease cases will drive the growth of the global erdosteine market.
The side effects of erdosteine
As much as the mucolytic agent, erdosteine is effective in managing and treating chronic obstructive pulmonary diseases but can cause several side effects. It can cause headaches, nausea, stomach pain, and skin rashes. It can also lead to vomiting, itching, and diarrhoea. It can also alter the users' tastes. Furthermore, the onset of action after ingesting the drugs and the time it takes to have an effect are not clinically known. Though these side effects may not be severe or life-threatening, they can significantly alter the users' everyday life. Therefore, the side effects of erdosteine may limit the market's growth.
The rising government healthcare expenditure
The growing technological advancements, product innovations and scientific breakthroughs have led to a better healthcare demographic globally. Life expectancy has increased, the death threats have fallen, and several life-threatening diseases/infections have been eradicated with consistent policy interventions. The world has moved on from treating prevalent virulent conditions towards preventing and managing them with regular vaccinations, robust diagnostics and monitoring infrastructure. Healthcare expenditure has gradually increased in infrastructural, research, development, and services. Furthermore, the covid19 pandemic highlighted several drawbacks in the healthcare infrastructure in several countries. Therefore, the covid 19 pandemic has led to a renewed fiscal push towards advancing healthcare services to the average populace.
Additionally, the contemporary world poses different problems to the healthcare industry. For instance, the rising consumption of tobacco, cigarette smoking and levels of air pollution has contributed to the increasing cases of chronic pulmonary conditions. Therefore, there is a more significant fiscal push towards preventing these cases by creating awareness and offering regular check-ups, diagnostic and treatment options. The renewed budgetary spending is also utilized for ramping up the pharmaceutical sector. The rising government healthcare expenditure will provide lucrative market opportunities in the forecast period.
The poor healthcare infrastructure in low- and middle-income countries
A significant proportion of the COPD population resides in low-and-middle-income countries. Similarly, a substantial proportion of death caused by COPD happens in low- and middle-income countries. Indoor pollution in developing nations caused by using wood fuel for cooking and other domestic purposes is one of the reasons for this trend. These nations have poor healthcare infrastructure with insufficient medications, personnel or logistics. Access to life-saving drugs is difficult in these nations. The large population of these countries is left out of the potential erdosteine market. Therefore, the poor healthcare infrastructure in low- and middle-income countries will challenge the global market.
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region emerged as the most prominent global erdosteine market, with a 45% market revenue share in 2022. The young population in the region is highly vulnerable to smoking and tobacco consumption. The growing popularity of e-cigarettes also adds to the already prevalent menace of substance abuse in the region. The stressful contemporary lifestyle has also increased tobacco consumption and cigarette smoking, given the stressful work life or life in general.
Furthermore, occupational exposure to undesirable particulate matter and growing air pollution in the region contribute to chronic pulmonary conditions/diseases. The robust drug supply from the extensive and ever-expanding pharmaceutical sector meets the demand for erdosteine. The presence of big pharma companies drives the research and development of novel drugs in the region, thereby augmenting the region's growth. The vast and structured network of distributors and retailers like CVS boost the region's growth. The rising government healthcare expenditure will contribute to the regional erdosteine market's development in the forecast period.
North America region Erdosteine Market Share in 2022 - 45%
Check the geographical analysis of this market by requesting a free sample
The end user is divided into pharmaceuticals, research institutes, contract manufacturing organizations and others. The pharmaceutical segment dominated the market with a market share of around 43% in 2022. The expanding pharmaceutical sector of India and China have significantly contributed to the segment's growth in the market. The collaborations, mergers, acquisitions, partnerships and agreements between the market players to develop novel drugs and product innovation in the pharmaceutical sector will also drive the segment's growth. Furthermore, the vast and expansive distribution and retail network of drug stores aid the growth of the pharmaceutical by extending their reach and improving drug accessibility. The increasing research and development will also propel the segment's growth. Additionally, fiscal spending is anticipated to rise and aid the pharmaceutical sector in growing in the forecast period.
The application segment is divided into bronchitis, chronic obstructive pulmonary disease, nasopharyngitis and others. The chronic obstructive pulmonary disease segment dominated the market with a market share of around 42% in 2022. Chronic obstructive pulmonary disease (COPD) is a long-term, inflammatory lung condition that impairs airflow. Symptoms include wheezing, coughing up mucus (sputum), and trouble breathing. The growing geriatric population will increase the incidence of COPD.
Furthermore, the growing consumption of e-cigarettes and tobacco will also contribute to the rising prevalence of COPD globally. COPD is common, causing around 3 to 4 million deaths worldwide annually. If not managed, it is life-threatening and can lead to other fatal health conditions. Therefore, the increasing incidence and growing prevalence of the chronic obstructive pulmonary disease will propel the segment's growth.
|Market Size||Revenue (USD Million)|
|Market size value in 2022||USD 143 Million|
|Market size value in 2032||USD 341.96 Million|
|CAGR (2023 to 2032)||9.11%|
|Regional Segments||The regions examined for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa.|
|Segments||The research segment is based on end-user and application.|
As per The Brainy Insights, the size of the erdosteine market was valued at USD 143 million in 2022 to USD 341.96 million by 2032.
Global erdosteine market is growing at a CAGR of 9.11% during the forecast period 2023-2030.
The market's growth will be influenced by the rising prevalence of chronic obstructive pulmonary disease.
The side effects of erdosteine could hamper the market growth.
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By End User
4.3.2. Market Attractiveness Analysis By Application
4.3.3. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2.1. The rising prevalence of chronic obstructive pulmonary disease
5.3.1. The side effects of erdosteine
5.4.1. The rising government healthcare expenditure
5.5.1. The poor healthcare infrastructure in the low- and middle-income countries
6. Global Erdosteine Market Analysis and Forecast, By End User
6.1. Segment Overview
6.3. Research Institutes
6.4. Contract Manufacturing Organisations
7. Global Erdosteine Market Analysis and Forecast, By Application
7.1. Segment Overview
7.3. Chronic Obstructive Pulmonary Disease
8. Global Erdosteine Market Analysis and Forecast, By Regional Analysis
8.1. Segment Overview
8.2. North America
8.5. South America
8.6. Middle East and Africa
8.6.2. South Africa
9. Global Erdosteine Market-Competitive Landscape
9.2. Market Share of Key Players in the Erdosteine Market
9.2.1. Global Company Market Share
9.2.2. North America Company Market Share
9.2.3. Europe Company Market Share
9.2.4. APAC Company Market Share
9.3. Competitive Situations and Trends
9.3.1. Product Launches and Developments
9.3.2. Partnerships, Collaborations, and Agreements
9.3.3. Mergers & Acquisitions
10. Company Profiles
10.1. Alitair Pharmaceuticals
10.1.1. Business Overview
10.1.2. Company Snapshot
10.1.3. Company Market Share Analysis
10.1.4. Company Product Portfolio
10.1.5. Recent Developments
10.1.6. SWOT Analysis
10.2. Berchemia Healthcare
10.2.1. Business Overview
10.2.2. Company Snapshot
10.2.3. Company Market Share Analysis
10.2.4. Company Product Portfolio
10.2.5. Recent Developments
10.2.6. SWOT Analysis
10.3. Delta Finochem Pvt. Ltd.
10.3.1. Business Overview
10.3.2. Company Snapshot
10.3.3. Company Market Share Analysis
10.3.4. Company Product Portfolio
10.3.5. Recent Developments
10.3.6. SWOT Analysis
10.4. Edmond Pharmaceuticals
10.4.1. Business Overview
10.4.2. Company Snapshot
10.4.3. Company Market Share Analysis
10.4.4. Company Product Portfolio
10.4.5. Recent Developments
10.4.6. SWOT Analysis
10.5. Hanmi Pharmaceuticals Co. Ltd.
10.5.1. Business Overview
10.5.2. Company Snapshot
10.5.3. Company Market Share Analysis
10.5.4. Company Product Portfolio
10.5.5. Recent Developments
10.5.6. SWOT Analysis
10.6. Hikma Pharmaceuticals
10.6.1. Business Overview
10.6.2. Company Snapshot
10.6.3. Company Market Share Analysis
10.6.4. Company Product Portfolio
10.6.5. Recent Developments
10.6.6. SWOT Analysis
10.7. Recipharm AB
10.7.1. Business Overview
10.7.2. Company Snapshot
10.7.3. Company Market Share Analysis
10.7.4. Company Product Portfolio
10.7.5. Recent Developments
10.7.6. SWOT Analysis
10.8. Shandong Luoxin Pharmaceuticals
10.8.1. Business Overview
10.8.2. Company Snapshot
10.8.3. Company Market Share Analysis
10.8.4. Company Product Portfolio
10.8.5. Recent Developments
10.8.6. SWOT Analysis
10.9. Shanghai Pukang Pharmaceutical
10.9.1. Business Overview
10.9.2. Company Snapshot
10.9.3. Company Market Share Analysis
10.9.4. Company Product Portfolio
10.9.5. Recent Developments
10.9.6. SWOT Analysis
10.10. Zhejiang Pharmaceuticals Co. Ltd.
10.10.1. Business Overview
10.10.2. Company Snapshot
10.10.3. Company Market Share Analysis
10.10.4. Company Component Portfolio
10.10.5. Recent Developments
10.10.6. SWOT Analysis
List of Table
1. Global Erdosteine Market, By End User, 2019-2032 (USD Million)
2. Global Pharmaceuticals Erdosteine Market, By Region, 2019-2032 (USD Million)
3. Global Research Institutes Erdosteine Market, By Region, 2019-2032 (USD Million)
4. Global Contract Manufacturing Organisations Erdosteine Market, By Region, 2019-2032 (USD Million)
5. Global Others Erdosteine Market, By Region, 2019-2032 (USD Million)
6. Global Erdosteine Market, By Application, 2019-2032 (USD Million)
7. Global Bronchitis Erdosteine Market, By Region, 2019-2032 (USD Million)
8. Global Chronic Obstructive Pulmonary Disease Erdosteine Market, By Region, 2019-2032 (USD Million)
9. Global Nasopharyngitis Erdosteine Market, By Region, 2019-2032 (USD Million)
10. Global Others Erdosteine Market, By Region, 2019-2032 (USD Million)
11. Global Erdosteine Market, By Region, 2019-2032 (USD Million)
12. North America Erdosteine Market, By End User, 2019-2032 (USD Million)
13. North America Erdosteine Market, By Application, 2019-2032 (USD Million)
14. U.S. Erdosteine Market, By End User, 2019-2032 (USD Million)
15. U.S. Erdosteine Market, By Application, 2019-2032 (USD Million)
16. Canada Erdosteine Market, By End User, 2019-2032 (USD Million)
17. Canada Erdosteine Market, By Application, 2019-2032 (USD Million)
18. Mexico Erdosteine Market, By End User, 2019-2032 (USD Million)
19. Mexico Erdosteine Market, By Application, 2019-2032 (USD Million)
20. Europe Erdosteine Market, By End User, 2019-2032 (USD Million)
21. Europe Erdosteine Market, By Application, 2019-2032 (USD Million)
22. Germany Erdosteine Market, By End User, 2019-2032 (USD Million)
23. Germany Erdosteine Market, By Application, 2019-2032 (USD Million)
24. France Erdosteine Market, By End User, 2019-2032 (USD Million)
25. France Erdosteine Market, By Application, 2019-2032 (USD Million)
26. U.K. Erdosteine Market, By End User, 2019-2032 (USD Million)
27. U.K. Erdosteine Market, By Application, 2019-2032 (USD Million)
28. Italy Erdosteine Market, By End User, 2019-2032 (USD Million)
29. Italy Erdosteine Market, By Application, 2019-2032 (USD Million)
30. Spain Erdosteine Market, By End User, 2019-2032 (USD Million)
31. Spain Erdosteine Market, By Application, 2019-2032 (USD Million)
32. Asia Pacific Erdosteine Market, By End User, 2019-2032 (USD Million)
33. Asia Pacific Erdosteine Market, By Application, 2019-2032 (USD Million)
34. Japan Erdosteine Market, By End User, 2019-2032 (USD Million)
35. Japan Erdosteine Market, By Application, 2019-2032 (USD Million)
36. China Erdosteine Market, By End User, 2019-2032 (USD Million)
37. China Erdosteine Market, By Application, 2019-2032 (USD Million)
38. India Erdosteine Market, By End User, 2019-2032 (USD Million)
39. India Erdosteine Market, By Application, 2019-2032 (USD Million)
40. South America Erdosteine Market, By End User, 2019-2032 (USD Million)
41. South America Erdosteine Market, By Application, 2019-2032 (USD Million)
42. Brazil Erdosteine Market, By End User, 2019-2032 (USD Million)
43. Brazil Erdosteine Market, By Application, 2019-2032 (USD Million)
44. Middle East and Africa Erdosteine Market, By End User, 2019-2032 (USD Million)
45. Middle East and Africa Erdosteine Market, By Application, 2019-2032 (USD Million)
46. UAE Erdosteine Market, By End User, 2019-2032 (USD Million)
47. UAE Erdosteine Market, By Application, 2019-2032 (USD Million)
48. South Africa Erdosteine Market, By End User, 2019-2032 (USD Million)
49. South Africa Erdosteine Market, By Application, 2019-2032 (USD Million)
List of Figures
1. Global Erdosteine Market Segmentation
2. Erdosteine Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Erdosteine Market Attractiveness Analysis By End User
9. Global Erdosteine Market Attractiveness Analysis By Application
10. Global Erdosteine Market Attractiveness Analysis By Region
11. Global Erdosteine Market: Dynamics
12. Global Erdosteine Market Share by End User (2022 & 2032)
13. Global Erdosteine Market Share by Application (2022 & 2032)
14. Global Erdosteine Market Share by Regions (2022 & 2032)
15. Global Erdosteine Market Share by Company (2022)
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. The Brainy Insights has segmented the erdosteine market based on below mentioned segments:
Erdosteine Market by End User:
Erdosteine Market by Application:
Erdosteine Market by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date